News
Earlier this month, Merck and Daiichi Sankyo announced that ifinatamab deruxtecan was granted Breakthrough Therapy Designation by the U.S. FDA for treating adult patients with extensive-stage small ...
Zacks Investment Research on MSN8h
ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth
AbbVie ABBV is known for its strong immunology franchise comprising blockbuster drugs like Skyrizi, Rinvoq and Humira.
DelveInsight's VEGFR-2 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback